ArticleBioprocess and biosystems engineering2026
Construction of an industrial host for the efficient active expression of protein glutaminase (PG) in Bacillus licheniformis.
Article in Bioprocess and biosystems engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Protein glutaminase (PG), a specific deaminase derived from C. proteolyticum, has been shown to hold significant potential for improving plant protein functionality. However, its industrial application is hindered by low expression level, inefficient activation from its proenzyme form (pro-PG), and high production costs in native or common heterologous hosts. To develop an effective industrial host for active expression of PG based on food-grade strain, the Bacillus licheniformis BL-LKT strain originated from enterprises was systematically modified and engineered. First, the extracellular polysaccharide (EPS) gene cluster was knocked out to alleviate cell aggregation, thereby enhancing cell growth and fermentation performance. Subsequently, a series of single and double knockout mutants of key extracellular protease genes (aprE, bpr, epr, vpr, wpr) were constructed to reduce the risk of PG hydrolysis by these proteases, while retaining sufficient proteolytic activity for pro-PG activation. The PG was then expressed in these engineered hosts using the shuttle vector pLY-3-PG. Among the constructed strains, the mutant EPE, which lacks eps, aprE, and epr, exhibited the highest PG activity of 0.537 U/mL, representing a 5.33-fold increase compared with the original strain. Fed-batch fermentation in a 5-L bioreactor ultimately yielded a PG activity of 2.35 U/mL, a 337.6% increase largely attributable to the activation by endogenous proteases. These findings provide a strong foundation for utilizing engineered B. licheniformis as an efficient and industrially viable chassis for the cost-effective production of active PG.
Indexed as
Identifiers
42873279What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.